AKESO(HK:09926) Zhi Tong Cai Jing·2025-08-26 12:41Core Insights - The company reported a revenue of 1.412 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 37.75% [1] - Gross profit reached 1.121 billion RMB, up 18.82% year-on-year, while R&D expenses were 731 million RMB, an increase of 23.02% compared to the previous year [1] Group 1: Financial Performance - Commercial sales revenue was approximately 1.402 billion RMB, a significant increase of 49.20% from 939 million RMB in the same period last year, driven by the inclusion of new products in the national medical insurance directory [1] - The company has upgraded its commercialization system, expanding its sales team to over 1,200 members, focusing on oncology and specialty drugs [1] Group 2: Product Pipeline and R&D - The company currently has over 50 innovative projects in development across oncology, autoimmune, and metabolic diseases, with 7 self-developed products approved for market [2] - 12 products are in Phase III clinical trials, and 12 are in Phase I/II clinical research, with 15 products being potential first-in-class or best-in-class innovations [2]